Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2005

View Archived Issues

Drug discovery targets for atherosclerosis

BPC-157 enhances healing during CO2 laser therapy

ADHD treatment consistency varies with methylphenidate formulations

Candesartan reduces new-onset diabetes in heart failure patients

Transdermal 4-hydroxytamoxifen demonstrates activity in breast cancer patients

Adenoviral interferon beta delivery feasible for pleural malignancies

Gene therapy with IL-10 ameliorates atherogenesis in mice

PPARalpha/delta agonists show beneficial effects on HDL-C in primates

Purdue Pharma suspends Palladone Capsules

Ortec to begin confirmatory OrCel trial

Updated labeling for Cialis, Levitra and Viagra

Brazilian patients receive Zilver PTX paclitaxel-coated stent for PAD

Xoma to terminate BPI agreement with Zephyr Sciences

Approvable letter for Pulminiq

Adherex enters into licensing deal with GlaxoSmithKline

ChemGenex plans registration-directed trials for Ceflatonin

Genaissance enters into HAP Technology agreement with Organon

Nautilus advances improved IFN-beta into preclinical development

MacroGenics signs agreement for anti-CD3 antibody for type 1 diabetes

Active Biotech's 57-57 successfully completes first clinical study

Antitumor efficacy reported for yttrium-90 microspheres

Sankyo to resume development of CS-917

Good safety and pharmacokinetic profile of XP-19986 in healthy volunteers

Rexin-G enters phase I study for pancreatic cancer

Recent patents describe novel antibacterial agents

LG Life Sciences claims new agents for acute hepatitis, liver cirrhosis and rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...